Pilot Study of a Mobile Phone Chatbot for Medication Adherence and Toxicity Management Among Patients With GI Cancers on Capecitabine.

Kelsey S Lau-Min¹, Jessica Marini², Nishant K Shah³, Donna Pucci⁴, Abigail N Blauch⁴, Christine Cambareri², Bethany Mooney⁴, Parul Agarwal⁴, Caleb Johnston⁵, Ryan P Schumacher⁵, Kyle White⁵, Peter E Gabriel³, Roy Rosin⁶, Linda A Jacobs⁴, Lawrence N Shulman⁴

¹Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.

²Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia, PA.

³Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

⁴Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

⁵Memora Health, San Francisco, CA.

⁶Center for Health Care Innovation, Penn Medicine, Philadelphia, PA.

PubMed DOI

Abstract

PURPOSE: Capecitabine is an oral chemotherapy used to treat many gastrointestinal cancers. Its complex dosing and narrow therapeutic index make medication adherence and toxicity management crucial for quality care. METHODS: We conducted a pilot study of PENNY-GI, a mobile phone text messaging-based chatbot that leverages algorithmic surveys and natural language processing to promote medication ad…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.